
Tempus AI (NasdaqGS:TEM) received FDA 510(k) clearance for Tempus ECG-PH, an AI-enabled tool that flags signs of pulmonary hypertension from standard ECGs. The newly cleared product is the third FDA-cleared offering in Tempus AI's cardiovascular portfolio, expanding the company beyond its core oncology genomics focus. Tempus ECG-PH is designed to help clinicians identify a condition that can be challenging to diagnose using conventional methods, addressing a key unmet need in cardiovascular...




















